NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the potential for the novel catalytic mechanism of CNM-Au8 as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases. The article is coauthored by lead investigators at the University of South Carolina and Clene.
According to the announcement, this study suggested that the robust neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity. The study was conducted by Hui Wang, PhD., a professor at the University of South Carolina, and a group of graduate students. “CNM-Au8 represents a new way to address the multiple assaults on neuronal health that occur during the course of neurodegenerative diseases,” said Clene vice president of translational medicine and study coauthor Karen S. Ho, PhD, in the press release. “Its catalytic activity strikes at a core metabolic deficiency and enables neurons to survive and function in a challenging environment that would otherwise lead to cell death. The remarkable promise of CNM-Au8 to address multiple different neurodegenerative diseases using this catalytic mechanism is truly exciting.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the potential for the novel catalytic mechanism of CNM-Au8 as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases. The article is coauthored by lead investigators at the University of South Carolina and Clene.
According to the announcement, this study suggested that the robust neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity. The study was conducted by Hui Wang, PhD., a professor at the University of South Carolina, and a group of graduate students. “CNM-Au8 represents a new way to address the multiple assaults on neuronal health that occur during the course of neurodegenerative diseases,” said Clene vice president of translational medicine and study coauthor Karen S. Ho, PhD, in the press release. “Its catalytic activity strikes at a core metabolic deficiency and enables neurons to survive and function in a challenging environment that would otherwise lead to cell death. The remarkable promise of CNM-Au8 to address multiple different neurodegenerative diseases using this catalytic mechanism is truly exciting.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
